By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.

SHANGHAI, China & JERSEY CITY, NJ, USA I March 28, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the ...

Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

Biosimilars including Filgrastim and Bevacizumab will be launched in Europe by July 2025. Aurobindo's China plant, with an ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Results: Forty trials were included in this meta-analysis. The Oxaliplatin, Fluorouracil, and Leucovorin (OFL) + sorafenib group and the sintilimab + bevacizumab biosimilar group decreased the risk of ...

Founded in 2010, TOT Biopharm is a Chinese biotech startup with a focus on oncology. As of August 2018, TOT is one of three Chinese companies racing to bring an Avastin (bevacizumab) biosimilar to the ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale ...

Avastin (bevacizumab) is a prescription drug used to treat certain types of cancer. Avastin is also available as a biosimilar drug. It’s prescribed for adults ages 18 years and older.

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

“We are proud to achieve the approval of the first biosimilar to omalizumab in the U.S., which will help broaden access to this important medicine for patients with allergic and respiratory conditions ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...